Tumour-infiltrating lymphocyte cancer therapy nears FDA finish line

For 35 years, researchers have been working to harness the cancer-fighting power of T cells in patients' tumours. Now, the first such product could be approved by the US FDA in the next few months.

Read about why the potential of these tumour-infiltrating lymphocytes to transform the treatment of solid tumours - as CAR-T cells have for some blood cancers - has kept researchers persisting in the face of manufacturing, regulatory and commerical challenges, as well as emerging directions to improve on first-generation approaches in this news article by Asher Mullard, which is freely accessible for the next week.